Kezar Life Sciences (KZR) Stock

Kezar Life Sciences (KZR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

The U.S. Food and Drug Administration has placed a clinical hold on Kezar Life Sciences' trial of experimental drug for lupus, the company said on Friday.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing a novel small molecule to treat unmet needs in immune-mediated diseases, today announced that it was informed via teleconference with the U.S. Food and Drug Administration (FDA) that the zetomipzomib Investigational New Drug (IND) application for the treatment of lupus nephritis (LN) has been placed on clinical hold. This action follows Kezar's communication t.

Kezar Life Sciences said on Monday it was stopping enrollment of new patients and dosing of ongoing patients in its mid-stage study for treating a symptom of lupus, following the recommendation of an independent committee after four deaths.

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer, today announced that the Compensation Committee of the company's Board of Directors granted one employee a nonqualified stock option to purchase 80,000 shares of its common stock with an exercise price of $0.71 per share, which is equal to the closing price of Kezar'.